Journal of the National Comprehensive Cancer Network
Scope & Guideline
Advancing Oncology: Pioneering Research for Better Patient Outcomes
Introduction
Aims and Scopes
- Multidisciplinary Cancer Care Approaches:
The journal emphasizes collaborative strategies that integrate various specialties in oncology, ensuring a holistic approach to cancer treatment and patient management. - Guideline Development and Updates:
JNCCN is known for its regular updates to clinical practice guidelines, providing oncologists with evidence-based recommendations to improve patient care. - Patient-Reported Outcomes and Quality of Life:
Research focusing on patient perspectives, including quality of life assessments and symptom management, is a significant area, highlighting patient-centered care. - Health Disparities and Equity in Cancer Care:
The journal addresses systemic inequities in cancer treatment, aiming to improve access and outcomes for underrepresented populations. - Innovative Therapies and Treatment Modalities:
Emerging therapies, including immunotherapy, targeted therapies, and personalized medicine, are frequently explored, showcasing advancements in treatment options. - Real-World Evidence and Implementation Science:
Research utilizing real-world data to inform clinical practice and guide treatment decisions is a key focus, helping to bridge the gap between research and practical application. - Cost-Effectiveness and Economic Evaluations:
Economic analyses related to cancer treatments and interventions are highlighted, emphasizing the importance of cost considerations in oncology.
Trending and Emerging
- Integration of Artificial Intelligence in Oncology:
The increasing use of AI in diagnostics, treatment planning, and patient management is becoming a prominent theme, reflecting the technological advancements in healthcare. - Health Equity Initiatives:
Research focusing on reducing health disparities and improving access to cancer care for marginalized populations is gaining traction, highlighting the journal's commitment to equitable healthcare. - Patient-Centered Care Models:
There is a growing emphasis on research that explores patient experiences, shared decision-making, and the incorporation of patient feedback into care protocols. - Telemedicine and Remote Care Solutions:
The COVID-19 pandemic has accelerated the adoption of telemedicine, and the journal is increasingly publishing studies on its efficacy and implementation in oncology. - Genomic Profiling and Personalized Medicine:
Research on genetic testing and personalized treatment strategies is expanding, reflecting the shift towards tailoring cancer therapies based on individual patient profiles. - Real-World Evidence and Outcomes Research:
There is an increasing focus on studies that utilize real-world data to evaluate treatment effectiveness and inform clinical guidelines, bridging the gap between research and practice.
Declining or Waning
- Traditional Chemotherapy Protocols:
As newer therapies gain traction, traditional chemotherapy regimens are receiving less emphasis, with a shift towards personalized and targeted treatments. - Single-Site Cancer Studies:
Research focused solely on single institutions or limited geographic areas is declining, as there is a growing preference for multi-center and population-based studies. - Basic Science Research in Oncology:
While foundational research is crucial, the journal has seen a decrease in the publication of purely basic science studies, favoring translational and clinical research that directly impacts patient care. - General Screening Guidelines:
With the increasing focus on personalized medicine and risk-based screening approaches, general cancer screening guidelines are becoming less central in the journal's publications. - Anecdotal Case Reports:
There is a noticeable decrease in the publication of anecdotal case reports, as the journal aims to prioritize studies with broader implications and robust data.
Similar Journals
Clinical Genitourinary Cancer
Pioneering discoveries for improved patient outcomes.Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.
ONCOLOGIST
Uniting voices in the fight against cancer.ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.
International Journal of Clinical Oncology
Pioneering Discoveries in Clinical OncologyInternational Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.
United European Gastroenterology Journal
Empowering research for better patient outcomes.The United European Gastroenterology Journal, published by John Wiley & Sons Ltd, is a leading publication in the fields of gastroenterology and oncology, boasting a distinguished Q1 ranking in both categories for 2023. With an ISSN of 2050-6406 and an E-ISSN of 2050-6414, this journal serves as a vital platform for disseminating cutting-edge research and innovative practices from 2013 to 2024, supporting the advancement of knowledge in gastrointestinal health and cancer treatment. With a commendable Scopus Rank of 14th out of 167 in gastroenterology and 54th out of 404 in oncology, it emphasizes the significance of impactful research in these critical areas. While currently not an open-access journal, it remains a vital resource for researchers, professionals, and students seeking comprehensive insights and evidence-based approaches to improve patient care and clinical outcomes. The United European Gastroenterology Journal is committed to bridging the gap between research and practice, making it an essential reference for those dedicated to the fields of gastroenterology and oncology.
CLINICAL ONCOLOGY
Fostering Collaboration for Breakthroughs in Cancer TreatmentClinical Oncology is a prestigious peer-reviewed journal published by Elsevier Science London, focusing on the dynamic fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an impressive impact factor reflecting its high-quality research contributions, the journal is ranked in the second quartile for oncology and the first quartile for radiology, underscoring its importance in advancing clinical knowledge and practice. Established in 1975, Clinical Oncology offers researchers, healthcare professionals, and students robust access to cutting-edge studies, reviews, and clinical trials that drive innovation and improve patient care. Based in the United Kingdom, the journal plays a vital role in disseminating significant findings, fostering collaboration, and enhancing education in the biosciences, particularly for those committed to addressing the challenges in cancer treatment and diagnostics. Given its rigorous selection criteria and broad readership, Clinical Oncology remains an essential resource for anyone dedicated to the fields of oncology and radiology.
JCO Oncology Practice
Enhancing Patient Outcomes with Groundbreaking Oncology InsightsJCO Oncology Practice is a premier peer-reviewed journal published by Lippincott Williams & Wilkins, specializing in the intersection of oncology and health policy. Established as a vital resource since 2020, this journal serves as a platform for the dissemination of innovative research, policy analysis, and clinical practice advancements aimed at enhancing cancer care. With its impressive impact factor and recognition in the top quartile (Q1) across multiple categories including Health Policy and Oncology, JCO Oncology Practice ranks #3 in Oncology Nursing and consistently shares cutting-edge insights that drive improvements within the field. The journal is accessible to a broad audience through its open access options, ensuring that vital knowledge reaches practitioners, researchers, and students alike. By prioritizing the latest evidence-based practices and addressing contemporary challenges in cancer treatment, JCO Oncology Practice plays an essential role in shaping the future of oncology practice and policy in the United States and beyond.
Hepatoma Research
Transforming Knowledge into Clinical PracticeHepatoma Research is a pivotal academic journal dedicated to advancing the field of hepatology and oncology, published by OAE PUBLISHING INC. Launched in 2019, this open-access journal has quickly established itself as a valuable resource for researchers and professionals dedicated to the study of liver cancer and related disorders. With an ISSN of 2394-5079 and E-ISSN 2454-2520, it offers insightful research articles and reviews aimed at enhancing clinical practices and understanding the complexities surrounding hepatoma. The journal is ranked in the Q3 category for both hepatology and oncology as of 2023, reflecting its commitment to quality amidst a competitive landscape. With its Scopus rankings placing it at the 47th percentile in hepatology and the 39th percentile in oncology, Hepatoma Research continues to be a crucial platform for disseminating groundbreaking findings. This journal underscores the importance of collaborative research and encourages submissions that contribute to the global discourse on liver cancer treatment and management.
Practical Radiation Oncology
Fostering Excellence in Radiation TherapyPractical Radiation Oncology is a premier journal published by Elsevier Science Inc., focusing on the critically important fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an ISSN of 1879-8500, this journal serves as an essential resource for professionals and researchers dedicated to advancing the practice and research of radiation oncology. Established in 2011 and continuing through 2024, it has quickly gained recognition, achieving a prestigious Q2 ranking in Oncology and an exceptional Q1 ranking in Radiology, Nuclear Medicine, and Imaging as of 2023. The journal, housed in New York, USA, provides a platform for innovative research and practical insights, aimed at enhancing therapeutic practices and improving patient outcomes. As part of its commitment to fostering scientific dialogue, it also features a range of articles, reviews, and clinical studies that cater to the diverse interests of its readers. Hard-copy availability combined with digital access ensures a broad reach for the latest advancements in the field.
LANCET ONCOLOGY
Empowering the oncology community with cutting-edge knowledge.The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.
Translational Oncology
Transforming Cancer Insights into Clinical SolutionsTranslational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.